

R3 Medical Research Publishes Peer Reviewed Article on Stem Cell Therapy for Autism Spectrum Disorder

R3 Medical Research, a division of R3 Stem Cell, has successfully published a peer reviewed article on Stem Cell Therapy for Autism Spectrum Disorder (ASD).

SCOTTSDALE, ARIZONA, UNITED STATES, March 27, 2023

/EINPresswire.com/ -- R3 Medical

Research, a division of R3 Stem Cell,

has successfully published a peer reviewed article on [Stem Cell Therapy for Autism Spectrum Disorder \(ASD\)](#). The article is a comprehensive review on all completed clinical trials of stem cell therapies for ASD.



“

Our Centers offer more procedures from autism globally than ANY other regenerative clinics. R3's treatments are the most affordable regenerative therapies available!"

David Greene, MD, PhD, MBA

Worldwide, it is estimated that 1 in 160 children have ASD. Traditional treatment options often fall well short of parent expectations, hence, the prospect of utilizing stem cell therapy for ASD is exciting and innovative.

The article is in the journal Regenerative Medicine and titled, "The promise of autologous and allogeneic cellular therapies in the clinical trials of autism spectrum disorder." The R3 research team, led by Sabiha Shamim, took a deep look at the ten completed clinical studies published on

[clinicaltrials.gov](#) which evaluated stem cell therapy for ASD.

The cell types used in the various studies included fetal stem cells, mesenchymal stem cells, bone marrow stem cells, adipose stem cells, [umbilical cord-derived stem cells](#), neural stem cells and hematopoietic stem cells. Application of the stem cells was achieved either solely through intravenous infusion, or through intrathecal injection.

Apart from some common minor adverse events such as vomiting, nausea and mild pain, the

results of the trials propose this therapy to be safe for different age groups. Most of the studies showed improved behavior and communication in those with ASD, although limited sample size affected the statistical significance.

Globally, R3 Stem Cell offers stem cell therapy for autism in Pakistan and several other countries (e.g. Mexico, India, Philippines, South Africa). According to R3 CEO David Greene, MD, PhD, MBA, "Our Centers offer more procedures from autism globally than ANY other regenerative clinics. Our skilled providers perform conscious sedation when needed, high stem cell counts, and combine exosomes with the biologics to improve outcomes. R3's treatments are the most affordable regenerative therapies available!"

R3 Stem Cell offers free consultations to families looking to see if their children with ASD are candidates for regenerative therapies. Visit <https://r3stemcell.com> for more information and call +1 (844) GET-STEM to schedule the virtual consultation.

David Greene, MD, PhD, MBA
R3 Medical Research
+ +1 844-438-7836
[email us here](#)

Review

For reprint orders, please contact: reprints@futuremedicine.com



The promise of autologous and allogeneic cellular therapies in the clinical trials of autism spectrum disorder

Sabiha Shamim¹, Nasar Khan^{1,1,2}, David L Greene^{1,2}, Umm E Habiba¹ & Amna Umar¹

¹Bello Bio Labs & Therapeutics (BBLT) Pvt. Ltd, Asharqi Multiplex, Peshawar Road, Sector H-13 Islamabad, 44000, Pakistan

²R3 Medical Research LLC, 10045 East Dynamic Boulevard Suite 200, Scottsdale, AZ 85262, United States of America

*Author for correspondence: nkhan@r3stemcell.com

¹Authors contributed equally

Autism spectrum disorder (ASD) is a consortium of developmental conditions. As scientists have not yet identified the exact underlying cause for these disorders, it is not easy to narrow down a singular therapy to propose a reliable cure. The preponderance of research suggests that stem-cell therapy improves aspects of outcome measure scales in patients with ASD; therefore, future studies should give us more confidence in the results. This overview considers the data that have emerged from the small set of published trials conducted using different approaches in stem-cell therapy for ASD, evaluates their results and proposes additional steps that could be taken if this field of endeavor is to be pursued further.

Tweetable abstract: Summary of the current trends and outcomes of clinical trials conducted using different autologous and allogeneic cellular approaches to investigate cellular therapies' use, safety and efficacy in treating autism spectrum disorder.

First draft submitted: 10 October 2022; Accepted for publication: 2 March 2023; Published online: 20 March 2023

Keywords: allogeneic • autism spectrum disorder • autologous • cellular therapy • mesenchymal stem cells • stem cells

'Autism' was initially used as a diagnostic term in 1943 to describe a particular syndrome seen in children who displayed typical symptoms such as impaired social and emotional connections at an early age [1]. Autism is defined by a substantial impairment in social communication as well as unusual repetitive and/or restricting behaviors or interests [2]. Henceforth, the term has come to be known as autism spectrum disorder (ASD), which is a neurodevelopmental disorder according to the definitions of the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, fifth edition) by the American Psychiatric Association and the ICD-10 (International Classification of Diseases, tenth revision) by WHO [3].

ASD includes several conditions that were previously considered separate entities. These include autism, Asperger's syndrome, childhood disintegrative disorder and an unspecified form of pervasive developmental disorder. Patients with ASD show a wide range of variations in symptoms, condition severity and functional disability [3]. Although scientists have not yet been able to determine the exact cause leading to ASD, it has been theorized that disturbances caused during the embryonic stages may be responsible [4]. ASD may be divided into two main symptom categories:

- Reduced social interaction;
- Repetitive behaviors, curiosities and aggressive actions.

Screening of all newborns is advised by the American Academy of Pediatrics for the presence of early indicators of autism. Autistic children can be diagnosed using evaluation scales such as the Autism Diagnostic Observation

Future
Medicine

10.2217/1746-0751.2022.0176 © 2023 R3 Medical Research LLC

Regen. Med. (Epub ahead of print)

ISSN 1746-0751



corporate vision
Future of better business

Your 2022 WINNER

2022 Corporate Excellence Awards

R3 Stem Cell
Most Outstanding Regenerative
Medicine Company - 2022



This press release can be viewed online at: <https://www.einpresswire.com/article/624658742>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.